Epithalon
Also known as: Epitalon, Epithalamin, Alanyl-glutamyl-aspartyl-glycine
Four-amino-acid peptide developed by Vladimir Khavinson's group in Russia and studied for aging. The evidence is mostly from cell and animal studies.
Evidence
Emerging
FDA status
Not FDA-approved
Source
Synthetic tetrapeptide derived from pineal gland peptides
Overview
Four-amino-acid peptide developed by Vladimir Khavinson's group in Russia and studied for aging. The evidence is mostly from cell and animal studies.
Mechanism of Action
Reported in cell studies to activate telomerase, regulates gene expression via epigenetic mechanisms, enhances Nrf2 activation to reduce oxidative stress, stimulates pineal melatonin production, inhibits pro-senescence genes (CCl11, HMGB1).
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Telomerase activity in cell studies
- Cell aging in lab studies
- Melatonin and circadian rhythm in animal studies
- Oxidative stress in animal studies
- Immune markers in animal studies
- Age-related markers in small Russian studies
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Epithalon can be requested through Gabriel. A licensed clinician at a telehealth partner reviews your request and decides whether it's appropriate. Gabriel never gives peptide dosing.
Compounded medications aren't FDA-approved. A licensed clinician decides what's right for you.
Research & Evidence
Khavinson's research group, preclinical animal studies
Evidence is limited to cell and animal studies and small studies from one research group in Russia. There is no good evidence that it lengthens telomeres or helps people live longer.
Safety Information
Potential Side Effects
- •Vivid dreams
- •Mild fatigue initially
Contraindications
- Pregnancy
- Breastfeeding
- Active cancer
Interactions
- ⚠None well-documented